[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JOP20190086A1 - مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب - Google Patents

مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب

Info

Publication number
JOP20190086A1
JOP20190086A1 JOP/2019/0086A JOP20190086A JOP20190086A1 JO P20190086 A1 JOP20190086 A1 JO P20190086A1 JO P20190086 A JOP20190086 A JO P20190086A JO P20190086 A1 JOP20190086 A1 JO P20190086A1
Authority
JO
Jordan
Prior art keywords
arrhythmia
treatment
naphthyridinone derivatives
present
naphthyridinone
Prior art date
Application number
JOP/2019/0086A
Other languages
English (en)
Inventor
Ruowei Mo
Sicong Geng
Kayo Yasoshima
Yunshan Peng
David Thomas Parker
Efthymiou Hatice Belgin Gulgeze
Fupeng Ma
Ken Yamada
Stefan Peukert
Lv Liao
Guillaume Barbe
Gregory Raymond Bebernitz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of JOP20190086A1 publication Critical patent/JOP20190086A1/ar

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يقدم الاختراع الحالي مركب بالصيغة (I) أو ملح مقبول صيدلانياً منها؛ حيث R1، R3-R6، X2 وX3 هي كما تم تعريفها في هذه الوثيقة، طريقة لتصنيع مركبات الاختراع، واستخداماتها العلاجية. يقدم الاختراع الحالي أيضاً توليفة من عوامل فعّالة صيدلانيًاً وتركيبة صيدلانية. صورة
JOP/2019/0086A 2016-10-21 2017-06-16 مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب JOP20190086A1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662410930P 2016-10-21 2016-10-21
CN2016102928 2016-10-21
US201662413292P 2016-10-26 2016-10-26

Publications (1)

Publication Number Publication Date
JOP20190086A1 true JOP20190086A1 (ar) 2019-04-18

Family

ID=60409317

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0086A JOP20190086A1 (ar) 2016-10-21 2017-06-16 مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب

Country Status (33)

Country Link
US (3) US10266531B2 (ar)
EP (2) EP4141006A1 (ar)
JP (1) JP7030802B2 (ar)
KR (1) KR102540872B1 (ar)
CN (1) CN109843887B (ar)
AU (2) AU2017344489C1 (ar)
BR (1) BR112019007863A2 (ar)
CA (1) CA3038624A1 (ar)
CL (1) CL2019001023A1 (ar)
CO (1) CO2019003894A2 (ar)
CR (1) CR20190201A (ar)
CU (1) CU24599B1 (ar)
DO (1) DOP2019000100A (ar)
EC (1) ECSP19026973A (ar)
ES (1) ES2934234T3 (ar)
FI (1) FI3529251T3 (ar)
HR (1) HRP20221516T1 (ar)
HU (1) HUE060882T2 (ar)
IL (1) IL266128B (ar)
JO (1) JOP20190086A1 (ar)
LT (1) LT3529251T (ar)
MX (1) MX2019004484A (ar)
PE (1) PE20190735A1 (ar)
PH (1) PH12019500849A1 (ar)
PL (1) PL3529251T3 (ar)
PT (1) PT3529251T (ar)
RS (1) RS63841B1 (ar)
SA (1) SA519401614B1 (ar)
SG (1) SG11201902529WA (ar)
SI (1) SI3529251T1 (ar)
TW (1) TWI759343B (ar)
UY (1) UY37445A (ar)
WO (1) WO2018073788A1 (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
AU2019291792B2 (en) * 2018-06-27 2022-09-29 Bristol-Myers Squibb Company Naphthyridinone compounds useful as T cell activators
WO2022074567A1 (en) * 2020-10-06 2022-04-14 Novartis Ag Pharmaceutical compositions comprising naphthyridinone derivatives and their use in the treatment of arrhythmia
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1022214A (en) 1963-01-31 1966-03-09 Sterling Drug Inc Novel 1,3-disubstituted-1,4-dihydro-4-oxo-1,7-naphthyridines and their preparation
IL51092A0 (en) 1976-12-10 1977-02-28 Abic Ltd Naphthyridine derivatives and their preparation
JPS57176956A (en) 1981-04-24 1982-10-30 Nissan Chem Ind Ltd Preparation of 1-(2',6'-dichlorophenyl)-2-indolinone
JPS57176958A (en) 1981-04-24 1982-10-30 Nissan Chem Ind Ltd 1-(2',6'-dichlorophenyl)-2-methylthioindole and its preparation
JPS57176957A (en) 1981-04-24 1982-10-30 Nissan Chem Ind Ltd Preparation of 1-(2',6'-dichlorophenyl)-2-indolinone
JPS57176959A (en) 1981-04-24 1982-10-30 Nissan Chem Ind Ltd 1-(2',6'-dichlorophenyl)-2,3bis(methylthio) indole and its preparation
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4559332A (en) 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
US4698341A (en) 1983-07-30 1987-10-06 Godecke Aktiengesellschaft Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis
US4767762A (en) * 1985-12-23 1988-08-30 Abbott Laboratories Tricyclic quinoline and naphthyride antibacterials
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
DE69129226T2 (de) 1990-01-24 1998-07-30 Douglas I. Woodside Calif. Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
AU1625192A (en) 1991-05-31 1992-12-03 Zeneca Limited Heterocyclic derivatives
WO1993011782A1 (en) 1991-12-19 1993-06-24 Southwest Foundation For Biomedical Research Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
WO1996012704A1 (fr) 1994-10-20 1996-05-02 Wakunaga Seiyaku Kabushiki Kaisha Nouveau derive de pyridone-carboxylate, ou sel de celui-ci, et antibacterien le contenant comme principe actif
ES2224235T3 (es) 1996-04-19 2005-03-01 Wakunaga Pharmaceutical Co., Ltd. Nuevos derivados del acido piridonacarboxilico o sus sales y agentes antibacterianos que contienen los mismos como ingredientes activos.
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
DE69724140T2 (de) 1996-11-28 2004-06-03 Wakunaga Pharmaceutical Co., Ltd. Pyridoncarbonsäurederivate oder ihre salze und diese als aktive bestandteile enthaltende medikamente
WO1999064400A1 (en) 1998-06-12 1999-12-16 Vertex Pharmaceuticals Incorporated INHIBITORS OF p38
CA2339484A1 (en) 1998-08-03 2000-02-17 Robert A. O'brien Pyridinones for the treatment of sexual dysfunction
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6803388B2 (en) 1999-09-23 2004-10-12 Pfizer, Inc. (R)-Chiral halogenated substituted n,n-bis-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity
EP1282410A2 (en) 2000-04-12 2003-02-12 Novartis AG Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
JP2003040866A (ja) 2001-07-31 2003-02-13 Nippon Kayaku Co Ltd N置換インドール誘導体、その製造法及びそれを有効成分とする害虫防除剤
US6677352B1 (en) * 2001-09-26 2004-01-13 Yamin Wang 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders
AU2003209388A1 (en) 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
JP2005529160A (ja) 2002-05-31 2005-09-29 バイエル・フアーマシユーチカルズ・コーポレーシヨン 糖尿病及び糖尿病−関連障害の処置のための化合物及び組成物
WO2004014914A1 (en) 2002-08-07 2004-02-19 Novartis Ag Organic compounds as agents for the treatment of aldosterone mediated conditions
CN100447142C (zh) 2002-11-18 2008-12-31 诺瓦提斯公司 咪唑并[1,5a]吡啶衍生物及治疗醛固酮所介导疾病的方法
WO2005026164A1 (en) 2003-09-18 2005-03-24 Altana Pharma Ag Pharmacologically active imidazo[4,5-c]pyridines
AU2004275718B2 (en) 2003-09-23 2008-02-07 Merck Sharp & Dohme Corp. Quinazoline potassium channel inhibitors
DE602005008416D1 (de) 2004-03-26 2008-09-04 Lilly Co Eli Verbindungen zur behandlung von dyslipidemie
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
DE102004018198A1 (de) 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
JP2008500999A (ja) 2004-05-28 2008-01-17 シュペーデル・エクスペリメンタ・アーゲー 複素環式化合物およびアルドステロンシンターゼ阻害薬としてのそれらの使用
US20080076784A1 (en) 2004-05-28 2008-03-27 Peter Herold Bicyclic, Nitrogen-Containing Heterocycles and Aromatase Inhibitors
CA2568165A1 (en) 2004-05-28 2005-12-15 Speedel Experimenta Ag Heterocyclic compounds and their use as aldosterone synthase inhibitors
NZ587547A (en) 2004-06-24 2012-09-28 Vertex Pharma Modulators of ATP-Binding Cassette Transporters
TW200611897A (en) 2004-07-09 2006-04-16 Speedel Experimenta Ag Organic compounds
DE102004054215A1 (de) 2004-11-10 2006-05-11 Merck Patent Gmbh Pyridopyrimidinonderivate
TW200716634A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716105A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
WO2007002559A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Pyrazole based lxr modulators
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
EP1783114A1 (en) 2005-11-03 2007-05-09 Novartis AG N-(hetero)aryl indole derivatives as pesticides
JP5460054B2 (ja) 2005-11-23 2014-04-02 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 腫瘍形成性ras特異的細胞障害性化合物およびその使用法
AR056888A1 (es) 2005-12-09 2007-10-31 Speedel Experimenta Ag Derivados de heterociclil imidazol
WO2007116908A1 (ja) 2006-04-04 2007-10-18 Taiyo Nippon Sanso Corporation メタン分離方法、メタン分離装置及びメタン利用システム
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808812A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
EP1886695A1 (en) 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
RU2009110442A (ru) 2006-08-25 2010-09-27 Новартис АГ (CH) Конденсированные производные имидазола для лечения нарушений, опосредованных альдостеронсинтазой, и/или 11-бета-гидроксилазой, и/или ароматазой
US8143278B2 (en) 2006-12-18 2012-03-27 Novartis Ag Organic compounds
BRPI0721290A2 (pt) 2006-12-18 2014-03-25 Novartis Ag Compostos orgânicos
WO2008076336A2 (en) 2006-12-18 2008-06-26 Novartis Ag Imidazoles as aldosterone synthase inhibitors
BRPI0809645A2 (pt) 2007-03-29 2014-09-23 Novartis Ag Espoiro-composots heterocíclicos
US8338406B2 (en) * 2008-02-22 2012-12-25 Otsuka Pharmaceutical Co., Ltd. Benzodiazepine compound and pharmaceutical composition
WO2010012745A2 (en) 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh Benzimidazoles
AU2010283632B2 (en) 2009-08-10 2016-08-25 Ucl Business Plc Reversible covalent linkage of functional molecules
GB0917571D0 (en) 2009-10-07 2009-11-25 Karobio Ab Novel estrogen receptor ligands
JP5894161B2 (ja) 2010-08-25 2016-03-23 ネオファーム カンパニー, リミテッド 新規の複素環化合物及びこれを用いた炎症性疾患治療用組成物
EP2524915A1 (en) 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
JP6018633B2 (ja) 2011-07-12 2016-11-02 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft アミノメチルキノロン化合物
US20150045305A1 (en) 2012-01-27 2015-02-12 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
EP2855472B1 (en) 2012-04-05 2016-09-14 Boehringer Ingelheim International GmbH Naphthyridinone derivatives as inhibitors of cytomegalovirus dna polymerase
US9067894B1 (en) 2013-03-07 2015-06-30 Vanderbilt University Compound, composition, and method of activating GIRK potassium channel and use of same for treating conditions of interest
TW201444558A (zh) 2013-03-15 2014-12-01 Melinta Therapeutics Inc 使用喹諾酮類抗生素治療淋病感染的方法
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AR096022A1 (es) 2013-04-11 2015-12-02 Basf Se Compuestos de pirimidinio sustituido, útiles para combatir plagas de animales
WO2015019347A1 (en) 2013-08-08 2015-02-12 Yeda Research And Development Company Ltd. Girk as a therapeutic target of immune disorders and a marker of b cell subtypes
EP3088399A4 (en) 2013-12-26 2017-10-25 Kinki University Alkoxycarbonyl hemiacetal-type ester prodrug of pyridone carboxylic acid antibacterial drug
BR112017003546A2 (pt) 2014-08-21 2017-12-05 Glaxosmithkline Ip Dev Ltd amidas heterocíclicas como inibidores de rip1 quinase como medicamentos
PE20180252A1 (es) * 2015-06-09 2018-02-02 Bayer Pharma AG Moduladores alostericos positivos del receptor muscarinico m2
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب

Also Published As

Publication number Publication date
RU2019115344A (ru) 2020-11-24
WO2018073788A1 (en) 2018-04-26
US20190263803A1 (en) 2019-08-29
HRP20221516T1 (hr) 2023-02-17
CU20190042A7 (es) 2019-11-04
BR112019007863A2 (pt) 2019-07-02
AU2017344489C1 (en) 2021-12-23
EP4141006A1 (en) 2023-03-01
CR20190201A (es) 2019-06-04
PH12019500849A1 (en) 2019-12-02
US11530213B2 (en) 2022-12-20
IL266128B (en) 2021-06-30
KR102540872B1 (ko) 2023-06-08
AU2020204341B2 (en) 2021-07-01
RS63841B1 (sr) 2023-01-31
ES2934234T3 (es) 2023-02-20
SG11201902529WA (en) 2019-05-30
AU2017344489A1 (en) 2019-04-11
CO2019003894A2 (es) 2019-04-30
CN109843887A (zh) 2019-06-04
CU24599B1 (es) 2022-06-06
DOP2019000100A (es) 2019-06-16
AU2017344489B2 (en) 2020-04-02
CA3038624A1 (en) 2018-04-26
JP2019531326A (ja) 2019-10-31
PE20190735A1 (es) 2019-05-23
PL3529251T3 (pl) 2023-01-30
FI3529251T3 (fi) 2023-01-13
ECSP19026973A (es) 2019-04-30
US10844055B2 (en) 2020-11-24
SA519401614B1 (ar) 2022-06-12
PT3529251T (pt) 2022-12-23
CL2019001023A1 (es) 2019-06-21
UY37445A (es) 2018-05-31
EP3529251A1 (en) 2019-08-28
KR20190066052A (ko) 2019-06-12
US10266531B2 (en) 2019-04-23
US20210284635A1 (en) 2021-09-16
TWI759343B (zh) 2022-04-01
IL266128A (en) 2019-06-30
CN109843887B (zh) 2022-05-10
AU2020204341A1 (en) 2020-07-16
JP7030802B2 (ja) 2022-03-07
MX2019004484A (es) 2019-08-05
SI3529251T1 (sl) 2023-01-31
HUE060882T2 (hu) 2023-04-28
US20180111932A1 (en) 2018-04-26
TW201819377A (zh) 2018-06-01
RU2019115344A3 (ar) 2021-02-20
LT3529251T (lt) 2023-01-10
EP3529251B1 (en) 2022-10-05

Similar Documents

Publication Publication Date Title
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX2016001400A (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
MX2020007023A (es) Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn).
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
SA519401614B1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
PH12019500328A1 (en) Aza-indazole compounds for use in tendon and/or ligament injuries
PH12016502246A1 (en) Carboxamide derivatives
EA201692298A1 (ru) Производные карбоксамидов
PH12020550763A1 (en) Pyridinone derivatives and their use as selective alk-2 inhibitors
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
PH12019500327A1 (en) Indazole compounds for use in tendon and/or ligament injuries
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
EA201991008A1 (ru) Новые производные нафтиридинона и их применение в лечении аритмии